Key result
Autologous myoblast injection in ischemic HF linked to a ~6% increase in dobutamine-stimulated LVEF.
Why the study?
Does percutaneous injection of autologous myoblasts improve regional and global LV function in patients with ischaemic heart failure?
Does percutaneous injection of autologous myoblasts improve regional and global LV function in patients with ischaemic heart failure?
p-value: p=<0.0001
Percutaneous injection of autologous myoblasts may improve contractile reserve and symptoms in patients with ischaemic heart failure at 1-year follow-up.
May enhance contractile reserve in ischaemic HF; hypothesis-generating and leaves open efficacy in randomized trials.
BACKGROUND: There is experimental evidence that transplanting skeletal myoblasts (SM) into the post-infarction myocardial scar improves regional and global left ventricular (LV) function. AIMS: To evaluate short- and long-term regional and global LV functional effects of percutaneously transplanted SM in patients with ischaemic heart failure. METHODS AND RESULTS: Ten patients (mean age 60+/-10 years, 8 males) with dilated ischaemic cardiomyopathy underwent percutaneous injection of autologous myoblasts. Regional and global LV function was evaluated by 2-dimensional echocardiography and tissue Doppler imaging (TDI) at rest and during low-dose dobutamine infusion to assess contractile reserve. After a baseline examination, sequential follow-ups were performed at 1, 3, and 6 months and 1 year. NYHA functional class decreased from 2.7+/-0.5 to 1.9+/-0.5 (p<0.01) at one year. LV function and volumes at rest remained unchanged while contractile reserve significantly improved during follow-up. At low-dose dobutamine infusion, the peak systolic velocity in the regions of myoblasts injection significantly increased at TDI examination (from 7.7+/-2.1 to 8.6+/-1.8 cm/s, p=0.02); LV ejection fraction improved (from 40+/-9% to 46+/-8%, p<0.0001) and end-systolic volumes decreased (from 56+/-28 to 50+/-25 ml/m(2), p=0.001) at 1 year. CONCLUSION: In patients with ischaemic heart failure, percutaneous injection of autologous myoblasts may improve regional and global LV systolic function during dobutamine infusion, at 1-year follow-up.
No takes yet. Share an insight, caveat, or question.
Biagini et al. (2006) studied Ischaemic heart failure (n=10). Percutaneous injection of autologous myoblasts was evaluated on Regional and global LV function at rest and during low-dose dobutamine infusion (p=<0.0001). Percutaneous injection of autologous myoblasts in patients with ischaemic heart failure improved LV ejection fraction during dobutamine infusion from 40% to 46% at 1 year (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: